New hope for advanced cancer patients: HRS-8364 trial begins
NCT ID NCT07446153
First seen Mar 17, 2026 · Last updated May 10, 2026 · Updated 6 times
Summary
This study tests a new drug called HRS-8364 in people with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 282 adults aged 18-75 will participate across multiple hospitals.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Liaoning Cancer Hospital & Institute
RECRUITINGShenyang, Liaoning, 110042, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Sixth Affiliated Hospital, Sun-Yat-Sen University
RECRUITINGGuangzhou, Guangdong, 510655, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.